
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. is positioned for significant growth, with expectations to meet or surpass growth targets for 2025 and 2026, aligning its revenue generation and price-to-earnings (P/E) ratios closer to industry peers. The recent FDA approval of AMP-002 is a pivotal development that alleviates prior regulatory uncertainties and opens new potential revenue streams for the company. Additionally, the firm's focus on technically challenging pharmaceutical products and a strong market presence in the U.S., China, and France further supports a positive outlook on its financial performance.
Bears say
Amphastar Pharmaceuticals Inc. faces a negative outlook due to several fundamental issues, including dependence on the U.S. market, which poses risks should any regulatory changes or competitive pressures arise. The company's focus on technically challenging products does not eliminate the risks associated with rising manufacturing costs and potential supply chain disruptions, which may impact profitability. Additionally, the limited geographical diversification beyond the U.S., China, and France raises concerns about the firm’s overall revenue stability in light of potential market fluctuations.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares